Skip to main content

Advertisement

SpringerLink
Log in

Advances and future directions in management of prostate cancer

  • Review Article
  • Published:
Indian Journal of Surgery Aims and scope Submit manuscript

Abstract

Despite the high cure rates of patients diagnosed and treated with prostate cancer, there is still room for improvement in management of these patients. This includes the identification of patients at highest risk for progression, the usage of focal therapies in low risk disease, and the continued improvement on established modalities. Through these avenues, the morbidity associated with treatment for prostate cancer can be vastly reduced, and thus patient outcomes improved. This article reviews the current treatment modalities and future directions for the treatment of localised prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Crawford ED (2009) Understanding the epidemiology, natural history, and key pathways involved in prostate cancer. Urology 73:S4–S10

    Article  PubMed  Google Scholar 

  2. Kulkarni GS, Lockwood G, Evans A, Toi A, Trachtenberg J, Jewett MA, Finelli A, Fleshner NE (2007) Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy. Cancer 109:2432–2438

    Article  PubMed  Google Scholar 

  3. D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, et al. (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969–974

    Article  PubMed  Google Scholar 

  4. Makarov DV, Trock BJ, Humphreys EB, Mangold LA, Walsh PC, Epstein JI, Partin AW (2007) Updated nomogram to predict pathologic stage of prostate cancer given prostatespecific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000–2005. Urology 69:1095–1101

    Article  PubMed  Google Scholar 

  5. Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, Du Chane J, Carroll PR (2005) The University of California, San Francisco Cancer of the Prostate Risk Assessment score: A straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 173:1938–1942

    Article  PubMed  Google Scholar 

  6. Zhao KH, Hernandez DJ, Han M, Humphreys EB, Mangold LA, Partin AW (2008) External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score. Urology 72:396–400

    Article  PubMed  Google Scholar 

  7. Kattan MW, Cuzick J, Fisher G, Berney DM, Oliver T, Foster CS, Moller H, Reuter V, Fearn P, Eastham J, et al. (2008) Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Cancer 112:69–74

    Article  PubMed  Google Scholar 

  8. Carter HB, Kettermann A, Warlick C, Metter EJ, Landis P, Walsh PC, Epstein JI (2007) Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 178:2359–2364; discussion 2364–2365

    Article  PubMed  Google Scholar 

  9. Dall’Era MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR, Meng MV, Kane CJ, Perez N, Master VA, et al. (2008) Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer 112: 2664–2670

    Article  PubMed  Google Scholar 

  10. Nanda A, Chen MH, Braccioforte MH, Moran BJ, D’Amico AV (2009) Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA 302: 866–873

    Article  CAS  PubMed  Google Scholar 

  11. D’Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW (2008) Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 299:289–295

    Article  PubMed  Google Scholar 

  12. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D (1999) Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341:1781–1788

    Article  CAS  PubMed  Google Scholar 

  13. Levy DA, Pisters LL, Jones JS (2009) Primary cryoablation nadir prostate specific antigen and biochemical failure. J Urol 182:931–937

    Article  CAS  PubMed  Google Scholar 

  14. Murat FJ, Gelet A (2008) Current status of high-intensity focused ultrasound for prostate cancer: technology, clinical outcomes, and future. Curr Urol Rep 9:113–121

    Article  PubMed  Google Scholar 

  15. Marberger M, Carroll PR, Zelefsky MJ, Coleman JA, Hricak H, Scardino PT, Abenhaim LL (2008) New treatments for localized prostate cancer. Urology 72:S36–S43

    Article  PubMed  Google Scholar 

  16. Moore CM, Pendse D, Emberton M (2009) Photodynamic therapy for prostate cancer—a review of current status and future promise. Nat Clin Pract Urol 6:18–30

    Article  CAS  PubMed  Google Scholar 

  17. D’Ambrosio DJ, Pollack A, Harris EE, Price RA Jr, Verhey LJ, Roach M 3rd, Demanes DJ, Steinberg ML, Potters L, Wallner PE, et al. (2008) Assessment of external beam radiation technology for dose escalation and normal tissue protection in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 70:671–677

    PubMed  Google Scholar 

  18. Cesaretti JA, Stone NN, Skouteris VM, Park JL, Stock RG (2007) Brachytherapy for the treatment of prostate cancer. Cancer J 13:302–312

    Article  PubMed  Google Scholar 

  19. Ficarra V, Novara G, Artibani W, Cestari A, Galfano A, Graefen M, Guazzoni G, Guillonneau B, Menon M, Montorsi F, et al. (2009) Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies. Eur Urol 55:1037–1063

    Article  PubMed  Google Scholar 

  20. Hu JC, Gu X, Lipsitz SR, Barry MJ, D’Amico AV, Weinberg AC, Keating NL (2009) Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA 302:1557–1564

    Article  CAS  PubMed  Google Scholar 

  21. Menon M, Kaul S, Bhandari A, Shrivastava A, Tewari A, Hemal A (2005) Potency following robotic radical prostatectomy: a questionnaire based analysis of outcomes after conventional nerve sparing and prostatic fascia sparing techniques. J Urol 174:2291–2296; discussion 2296

    Article  PubMed  Google Scholar 

  22. Krane LS, Bhandari M, Peabody JO, Menon M (2009) Impact of percutaneous suprapubic tube drainage on patient discomfort after radical prostatectomy. Eur Urol 56(2): 325–330. Epub 2009 Apr 17

    Article  PubMed  Google Scholar 

  23. Badani KK, Kaul S, Menon M (2007) Evolution of robotic radical prostatectomy: assessment after 2766 procedures. Cancer 110:1951–1958

    Article  PubMed  Google Scholar 

  24. Kaouk JH, Goel RK, Haber GP, Crouzet S, Desai MM, Gill IS (2008) Single-port laparoscopic radical prostatectomy. Urology 72:1190–1193

    Article  PubMed  Google Scholar 

  25. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, et al. (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360:1310–1319

    Article  CAS  PubMed  Google Scholar 

  26. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, et al. (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320–1328

    Article  PubMed  Google Scholar 

  27. Bickers B, Aukim-Hastie C (2009) New molecular biomarkers for the prognosis and management of prostate cancer—the post PSA era. Anticancer Res 29:3289–3298

    CAS  PubMed  Google Scholar 

  28. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, et al. (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349:215–224

    Article  CAS  PubMed  Google Scholar 

  29. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, et al. (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301:39–51

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Wake Forest University, Winston Salem, NC, 27103, USA

    Louis S. Krane, Manish N. Patel & Ashok K. Hemal

Authors
  1. Louis S. Krane
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Manish N. Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ashok K. Hemal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Louis S. Krane.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Krane, L.S., Patel, M.N. & Hemal, A.K. Advances and future directions in management of prostate cancer. Indian J Surg 71, 337–341 (2009). https://doi.org/10.1007/s12262-009-0091-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12262-009-0091-7

Keywords

Search

Navigation